AlgiPharma AS is a biopharmaceutical company with primary focus on respiratory diseases, wound healing and other conditions caused by microbial infections and biofilms.
The company’s vision is to be a leading biopharmaceutical company that develops disruptive alginate oligomer technologies in order to fight diseases effectively through innovative therapies.
AlgiPharma has successfully completed a phase 1 clinical trial for its initial drug candidate for respiratory diseases. The drug candidate has proven to be safe and well tolerated in healthy subjects.
|
|
|
